Immaturity of the Genetic-Related Market
First written in FY2016. 4 of 5 entries say "Restated". Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「These markets are still in their infancy and have not yet been established. Their future direction remains highly unclear and uncertain, and objective information is currently extremely scarce. Accordingly, there is no guarantee that the markets will necessarily develop as our group forecasts in the future.」
The immaturity of the gene-related market and uncertainty over market trends continued to be reported. - FY2019RestatedAnnual report
「These markets are still in their infancy and have not yet been established. Their future direction remains highly unclear and uncertain, and objective information is currently extremely scarce. Accordingly, there is no guarantee that the markets will necessarily develop as our group forecasts in the future.」
The immaturity of the gene-related market and uncertainty over market trends continued to be reported. - FY2018RestatedAnnual report
「These markets are still in their infancy and have not yet been established. Their future direction remains highly unclear and uncertain, and objective information is currently extremely scarce. Accordingly, there is no guarantee that the markets will necessarily develop as our group forecasts in the future.」
The immaturity of the gene-related market and uncertainty over market trends continued to be reported. - FY2017RestatedAnnual report
「These markets are still in their infancy and have not yet been established. Their future direction remains highly unclear and uncertain, and objective information is currently extremely scarce.」
The immaturity of the gene-related market and uncertainty over market trends continued to be reported. - FY2016First statedAnnual report
「These markets are still in their infancy and have not yet been established. Their future direction remains highly unclear and uncertain, and objective information is currently extremely scarce.」
The company stated that although it expects the biotechnology market to expand, there is no guarantee that the immature market will develop as forecast.